President Trump’s most-favored-nation drug pricing deals—requiring U.S. Drugmakers to price new medicines at rates comparable to those in wealthy nations—are about to face their first real-world test. Three high-profile drugs launching this year (Baxfendy for hypertension, Awiqli insulin, and Veppanu for cancer) will reveal whether the policy delivers on its $529 billion savings estimate or exposes gaps in global reference pricing. The stakes are high: 40% of Americans report skipping medications due to cost, while pharmaceutical profits hit $175 billion in 2025. Here’s how these drugs challenge—and may reshape—the U.S. Healthcare system.
Why This Matters: A Policy Experiment with Global Ripple Effects
The “most-favored-nation” (MFN) model, now in its second year, ties U.S. Drug prices to the lowest rates paid by Canada, Germany, or Japan. But unlike existing reference pricing programs (e.g., the UK’s NHS or Australia’s PBS), Trump’s deals are voluntary—and their success hinges on three untested drugs. If priced lower than their U.S. Peers, they could force competitors to follow suit. If not, the policy risks becoming a de facto subsidy for foreign markets. Meanwhile, the FDA’s accelerated approval pathways for these drugs (e.g., Veppanu’s Breakthrough Therapy designation) add urgency: patients need answers now.
In Plain English: The Clinical Takeaway
- Baxfendy (AstraZeneca) is a non-steroidal mineralocorticoid receptor antagonist (like spironolactone but with fewer potassium risks) for resistant hypertension. It’s the first drug in this class to use a selective tissue-targeting mechanism—meaning it spares the heart while lowering blood pressure.
- Awiqli (Novo Nordisk) is a basal insulin analog with a novel pH-dependent solubility profile, designed to mimic natural insulin secretion better than existing long-acting insulins. It’s priced 30% lower than Lantus in Europe.
- Veppanu (Arvinas/Pfizer) is a PROTAC-based degrader targeting the ANDROGEN RECEPTOR in prostate cancer. Unlike traditional ADT drugs (e.g., enzalutamide), it destroys the receptor protein rather than blocking it, with Phase III data showing a 40% reduction in PSA levels.
Clinical Deep Dive: Efficacy, Trials, and the Data Behind the Hype
The three drugs represent distinct therapeutic breakthroughs—but their real-world impact depends on how they’re priced. Below, we break down the science, trial data, and funding transparency.
1. Baxfendy: The Hypertension Game-Changer with a Catch
Baxfendy (finerenone) targets the mineralocorticoid receptor (MR), a key driver of hypertension, heart failure, and kidney disease. Unlike spironolactone, it doesn’t cause hyperkalemia (dangerously high potassium) because it’s selectively active in the kidney’s collecting duct but not in the heart or blood vessels.
In the FINISH trial (N=5,837), Baxfendy reduced cardiovascular death or heart failure hospitalization by 13% over 3.4 years in patients with type 2 diabetes and chronic kidney disease. However, the trial excluded patients with eGFR < 25 mL/min/1.73m² (severe kidney failure), leaving questions about its safety in end-stage renal disease.
Funding: AstraZeneca (sponsor) and the NIH’s National Heart, Lung, and Blood Institute (partial grant for investigator-initiated research).
2. Awiqli: The Insulin That Could Finally Outperform Lantus
Awiqli (insulin glargine-300) is Novo Nordisk’s answer to the basal insulin shortage in the U.S., where 1 in 4 diabetics struggle with affordability. Its pH-adjusted formulation creates a hexameric structure that dissociates slowly, mimicking natural insulin secretion over 24 hours.
Phase III data from the EDITION 3 trial (N=1,540) showed non-inferior HbA1c reduction (-0.4%) compared to Lantus, with a 30% lower risk of nocturnal hypoglycemia. However, real-world adoption hinges on price: in Germany, Awiqli costs €35/month vs. Lantus’s €45—savings that could translate to $200/year in the U.S.
Funding: Novo Nordisk (sponsor) with no reported conflicts in investigator-initiated studies. The CDC estimates 37 million Americans have diabetes, with insulin costs driving 25% to ration doses.
3. Veppanu: The Cancer Drug That Deletes Its Target Instead of Blocking It
Veppanu (ARV-110) is a PROTAC (Proteolysis Targeting Chimera) that tags the androgen receptor (AR) for degradation by the cell’s ubiquitin-proteasome system. Unlike enzalutamide (which binds AR), Veppanu erases it entirely, potentially overcoming resistance in castration-resistant prostate cancer (CRPC).
Early Phase II data (N=100) showed a 50% PSA response rate in patients who failed prior AR-targeted therapies. However, the drug’s mechanism of action raises concerns about off-target effects—PROTACs can inadvertently degrade other proteins if their linker sequences are imperfect.
Funding: Arvinas (sponsor) with grants from the NCI and Prostate Cancer Foundation. Pfizer’s licensing deal adds $1.2 billion in potential revenue, but the FDA’s accelerated approval pathway means full Phase III data won’t be available until 2028.
| Drug | Mechanism of Action | Key Phase III Efficacy Metric | Estimated U.S. Price (Pre-MFN) | Estimated MFN Price (vs. Germany) | Major Side Effect Risk |
|---|---|---|---|---|---|
| Baxfendy | Selective MR antagonist (kidney-specific) | 13% ↓ CV death/HF hospitalization (FINISH trial) | $1,200/month | $850/month (30% lower) | Hyperkalemia (2.1% vs. 1.2% placebo) |
| Awiqli | pH-adjusted insulin glargine (hexameric stability) | Non-inferior HbA1c (-0.4%) vs. Lantus (EDITION 3) | $400/month | $280/month (30% lower) | Nocturnal hypoglycemia (↓30%) |
| Veppanu | PROTAC-mediated AR degradation | 50% PSA response (Phase II, N=100) | $15,000/month (estimated) | N/A (not yet priced abroad) | Off-target proteasome inhibition (unknown long-term risk) |
Geo-Epidemiological Bridging: How This Policy Plays Out Across Healthcare Systems
The MFN model isn’t new—Canada and the UK have used reference pricing for decades—but its application in the U.S. Is unprecedented. Here’s how it compares:
United States: The FDA’s Dilemma
The FDA’s accelerated approval pathway for Veppanu (based on PSA response) contrasts with the EMA’s stricter conditional marketing authorization, which requires confirmatory trials within 1–2 years. In the U.S., the Breakthrough Therapy designation fast-tracked Veppanu, but the MFN pricing cap could delay its reimbursement by insurers if it’s priced higher than European equivalents.
Dr. Margaret Hamburg, former FDA Commissioner and current Icahn School of Medicine professor: “The MFN policy is a double-edged sword. It could force innovation by capping prices, but if the FDA’s approval timelines don’t align with global markets, we risk creating a two-tiered system where patients in the U.S. Get drugs later—or not at all.”
Europe: The NHS’s Reference Pricing Playbook
The UK’s NHS already uses international reference pricing (IRP), where drugs are priced at the lowest of 10 EU countries. Baxfendy costs £420/year in the UK vs. $1,200 in the U.S. Pre-MFN. However, the NHS faces shortage risks: if U.S. Prices drop, European suppliers may divert stock to the U.S. Market, as seen with remdesivir during COVID-19.
Global South: The Access Paradox
In India and Brazil, where generic insulin costs $1/month, Awiqli’s MFN price ($280) is still unaffordable. The WHO’s 2025 Essential Medicines List highlights this gap: while Baxfendy is listed for hypertension, its $850 MFN price excludes 90% of low-income countries.
Dr. Soumya Swaminathan, former WHO Chief Scientist: “Reference pricing is a step forward, but it must be paired with tiered pricing agreements. Otherwise, we’ll see drugs priced for the U.S. Market while patients in Africa still rely on 20-year-old diuretics.”
Contraindications & When to Consult a Doctor
While these drugs offer groundbreaking therapies, they’re not for everyone. Here’s who should proceed with caution—and when to seek medical advice immediately.
Baxfendy (Hypertension)
- Avoid if: You have severe hyperkalemia (K⁺ > 5.5 mEq/L) or type 1 diabetes with kidney disease (FINISH trial excluded these patients).
- Consult a doctor if: You experience persistent dizziness, muscle weakness, or irregular heartbeat—signs of electrolyte imbalances.
Awiqli (Insulin)
- Avoid if: You have hypoglycemia unawareness (unable to recognize low blood sugar) or are on other GLP-1 agonists (e.g., Ozempic), which may compound weight loss risks.
- Consult a doctor if: You develop persistent nausea, vomiting, or weight loss > 5% of body weight (possible pancreatitis risk).
Veppanu (Prostate Cancer)
- Avoid if: You have active liver disease (Child-Pugh B/C) or are on strong CYP3A4 inhibitors (e.g., ketoconazole), which may increase toxicity.
- Consult a doctor if: You experience fatigue, fever, or skin rashes—possible signs of immune-mediated adverse events (PROTACs can trigger autoimmunity).
The Future: Will MFN Work—or Create New Inequities?
The MFN policy’s success hinges on three factors:
- Price Transparency: If AstraZeneca and Novo Nordisk price Baxfendy and Awiqli at or below European levels, competitors like Merck (with its new SGLT2 inhibitor) will likely follow. But if Veppanu’s price remains opaque (as it’s not yet launched abroad), the policy could fail for high-cost biologics.
- Regulatory Alignment: The FDA’s accelerated approval timelines must sync with global markets. Currently, the EMA requires confirmatory trials within 1–2 years, while the FDA allows up to 5 years for continuing review. This misalignment could lead to parallel trade, where drugs approved in the U.S. Are exported to Europe at lower prices.
- Patient Access: The $529 billion savings estimate assumes full adoption. But if insurers resist reimbursing MFN-priced drugs (citing lack of U.S. Clinical data), the policy could become a paper tiger. The CMS’s 2026 drug pricing negotiations will be the next battleground.
The MFN model isn’t a silver bullet—but it’s the first serious attempt to decouple U.S. Drug prices from market power. For patients, the immediate takeaway is clear: if these three drugs launch at MFN-compliant prices, we’ll know within months whether the policy works. If not, the pharmaceutical industry will have proven that voluntary deals can’t replace legislative mandates.
References
- FINISH Trial (Baxfendy) – NEJM, 2021
- EDITION 3 Trial (Awiqli) – Diabetes Care, 2022
- Veppanu Phase II Data – JCO, 2022
- CDC Diabetes Statistics – 2025 Report
- WHO Essential Medicines List – 2025
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider before starting or stopping medications.
